Aspira Pathlab
add_icon

Aspira Pathlab

72.89
+3.14
(4.50%)
Market Cap
₹- Cr
PE Ratio
-
Volume
18,307.00
Day High - Low
₹73.23 - ₹70.00
52W High-Low
₹106.78 - ₹50.49
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
7.03
EBITDA
-
Dividend Yield
- %
ROE Growth %
-
Debt to Equity
-
Forecast For
Actual

Company News

View All News
Caret
negative
Aspira Pathlab Diagnostics Limited reported a net loss of ₹230.49 lakhs for the second quarter ended September 30, 2025, compared to a profit of ₹97.36 lakhs in the same period last year. The company's board approved the appointment of Mrs. Kiran Raghavendra Awasthi as Additional Independent Director for a five-year term starting November 12, 2025, subject to member approval. Mrs. Awasthi is a Chartered Accountant with 28 years of experience in accounts, finance, and taxation, and serves as Senior Partner at AMRG Associates. The company acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP for ₹13.00 lakhs, effective from June 30, 2025. Following this acquisition, the LLP ceased operations and is winding up, resulting in the company having no subsidiaries, associates, or joint ventures as of September 30, 2025.
neutral
Five acquirers - Arvind Karsandas Bhanushali, Deepali Arvind Bhanushali, Jay Arvind Bhanushali, Nikunj Velji Mange, and Raj Arvind Bhanushali - along with Shraddha Nikunj Mange have announced an open offer to acquire 26,76,180 equity shares representing 26% of Aspira Pathlab & Diagnostics Limited's total paid-up equity shares. The offer price is set at Rs. 55 per share. The company disclosed this information on September 26, 2025, noting that the open offer follows SEBI takeover regulations.
positive
Aspira Pathlab Approves Q1 FY26 Results and Appoints Woman Independent DirectorAug 12, 2025
Aspira Pathlab & Diagnostics Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. The company reported standalone revenue from operations of Rs 524.80 lakhs and profit after tax of Rs 46.94 lakhs. On a consolidated basis, revenue was Rs 524.80 lakhs with profit after tax of Rs 42.15 lakhs. The board appointed Dr. Alaka Keshav Deshpande as Additional Woman Independent Director for a three-year term from September 27, 2025 to September 26, 2028, subject to shareholder approval. The company also acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP for Rs 13.00 lakhs effective June 30, 2025.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
3,044.00
-
#1 -
-
-
-
-
41.02
1,939.30
-
#1 -
-
-
-
-
45.50
464.20
-
#1 -
-
-
-
-
45.43
1,010.85
-
#1 -
-
-
-
-
49.07
282.25
-
#1 -
-
-
-
-
29.71
319.55
-
#1 -
-
-
-
-
49.28
784.95
-
#1 -
-
-
-
-
44.09
22.45
-
#1 -
-
-
-
-
65.61
308.55
-
#1 -
-
-
-
-
49.13
520.20
-
#1 -
-
-
-
-
59.95
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Quarterly Financial Results

Quarterly Financials
Jun 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
3
4
5
6
6
6
5
Expenses
3
4
4
5
5
5
5
EBITDA
-0
-0
0
1
1
1
1
Operating Profit %
-17 %
-5 %
6 %
21 %
11 %
16 %
13 %
Depreciation
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
Profit Before Tax
-1
-1
0
1
0
1
0
Tax
0
0
0
0
0
0
0
Net Profit
-1
-1
0
1
0
1
0
EPS in ₹
-0.70
-0.49
0.05
0.96
0.30
0.66
0.41

Balance Sheet

Balance Sheet
2024
2025
Total Assets
15
18
Fixed Assets
7
7
Current Assets
4
5
Capital Work in Progress
0
0
Investments
0
0
Other Assets
8
11
Total Liabilities
15
18
Current Liabilities
2
2
Non Current Liabilities
3
3
Total Equity
10
12
Reserve & Surplus
-5
-3
Share Capital
10
10

Cash Flow

Cash Flow
2024
2025
Net Cash Flow
0
1
Investing Activities
0
0
Operating Activities
1
2
Financing Activities
-1
-1

Share Holding

% Holding
Jan 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
36.25 %
36.25 %
36.25 %
36.25 %
36.25 %
36.25 %
36.19 %
34.55 %
19.48 %
19.47 %
19.37 %
19.37 %
18.90 %
18.90 %
18.72 %
18.72 %
18.55 %
18.55 %
18.39 %
18.39 %
18.39 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
40.41 %
40.41 %
40.41 %
40.33 %
40.33 %
41.47 %
43.33 %
40.92 %
52.60 %
51.49 %
51.76 %
51.76 %
52.24 %
51.99 %
55.71 %
59.15 %
61.26 %
60.28 %
60.46 %
60.28 %
60.16 %
Others
23.34 %
23.34 %
23.34 %
23.42 %
23.42 %
22.28 %
20.48 %
24.54 %
27.91 %
29.04 %
28.87 %
28.87 %
28.86 %
29.11 %
25.57 %
22.13 %
20.19 %
21.18 %
21.15 %
21.33 %
21.45 %
No of Share Holders
536
535
535
710
852
868
955
1,141
1,300
1,300
1,371
1,371
1,406
1,351
1,512
1,695
1,706
1,593
1,741
1,770
1,755

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
16 Nov 2016 CHANGE OF NAME Change Of Name
NA
16 Nov 2016 0.00 0.00
27 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Sept 2024 32.42 41.39
12 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2024 50.14 61.75
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Feb 2025 77.00 70.07
16 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
16 May 2025 63.93 56.05
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 69.30 65.00
26 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Sept 2025 63.00 61.87
12 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2025 60.97 60.77

Announcements

Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateNov 12, 2025
Standalone Financial Results And Limited Review Report As On September 30 2025Nov 12, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On November 12 2025Nov 12, 2025
Board Meeting Intimation for The Board Meeting To Be Held On November 12 2025Nov 04, 2025
Announcement under Regulation 30 (LODR)-Open Offer - UpdatesOct 13, 2025
Draft Letter of OfferOct 13, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Disclosure Regarding Detailed Public Statement ("DPS") In Relation To The Open Offer To The Public ShareholdersOct 06, 2025
Detailed Public StatementOct 06, 2025
Announcement under Regulation 30 (LODR)-CessationSep 27, 2025
Announcement under Regulation 30 (LODR)-Public Announcement-Open OfferSep 26, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateSep 26, 2025
Appointment Of Secretarial Auditor Of The CompanySep 26, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 26, 2025
Public Announcement - Open OfferSep 26, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2025
Closure of Trading WindowSep 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 05, 2025
Letters Dispatched To Non-Email ShareholdersSep 04, 2025
Notice Convening 52Nd Annual General Meeting To Be Held On Friday September 26 2025 At 02.00 P.M Through Video Conferencing Mode.Sep 04, 2025
Reg. 34 (1) Annual Report.Sep 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Book Closure Record Date & E-Voting Intimation For The Purpose Of 52Nd Annual General Meeting.Aug 29, 2025
52Nd Annual General Meeting To Be Held On Friday September 26 2025 At 02.00 P.M (IST) Through Video Conferencing / Other Audio Visual Means.Aug 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 12, 2025
Unaudited Standalone & Consolidated Financial Results For The Quarter Ended June 30 2025Aug 12, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On August 12 2025Aug 12, 2025
Board Meeting Intimation for Approval Of Un-Audited Financial Results (Standalone & Consolidated) For The First Quarter Ended On June 30 2025 And To Transact Other Businesses.Aug 02, 2025
Re-Appointment Of Dr. Pankaj J. Shah (DIN:02836324) As Managing Director & CEO For A Period Of Three (3) Years. Jul 10, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJul 10, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Inauguration Of Three (3) New Diagnostics Centers In Gujarat.Jul 01, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 01, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 10, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotJun 09, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Jun 02, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015May 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 17, 2025
100% Acquisition Of Stake And Strike Off Of Aspira DNA Diagnostics Gujarat LLPMay 16, 2025
Re-Appointment Of Dr. Pankaj Shah (DIN: 02836324) As Managing Director & CEO Subject To The Members Approval For A Period Of Three (3) YearsMay 16, 2025
Intimation Of Appointment Of Secretarial Auditor And Internal AuditorMay 16, 2025
Integrated Filing (Financial)May 16, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Dated May 16 2025May 16, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Dated May 16 2025May 16, 2025
Board Meeting Intimation for Approval Of Audited Standalone & Consolidated Financial Results Of The Company Alongwith The Auditor Report As On March 31 2025May 07, 2025
Updation In Contact Details Of The Company Registrar And Share Transfer AgentApr 22, 2025

Technical Indicators